BPC-157 and TB-500 (Wolverine stack)
Does stacking BPC-157 with TB-500 heal injuries faster than either one alone?
Reviewed by the amino101 editorial team. .
Also searched as Wolverine protocol, BPC-157 TB-500 blend, BPC TB-500 stack, Wolverine peptide stack.
BPC-157 is a 15 amino acid fragment of a protective protein found in human gastric juice. People use it for tendon, ligament, muscle and gut healing, and it is one of the most widely used research peptides in the recovery space.
TB-500 is a synthetic version of the active region of thymosin beta-4, a protein found in nearly every human cell that regulates actin and cell movement. It is used for injury recovery, flexibility and general tissue repair, usually alongside BPC-157.
People combine BPC-157 and TB-500 because the two are thought to work on different parts of the healing process. BPC-157 is dosed in micrograms, usually near the injury, and the rodent work shows it driving new blood vessel growth and pulling fibroblasts into damaged tendon. TB-500 is dosed in milligrams, works systemically, and regulates actin so cells can move into a wound. The evidence for the combination is anecdote layered on two separate animal literatures. No human trial has tested the pair, and no human trial has tested either peptide for a sports injury on its own. Both are unapproved and prohibited by WADA.
The nickname comes from forums and vendors, not from any product. This is the most searched peptide stack by a wide margin, and most of the questions behind that search are practical: how much of each, whether the two go in one syringe, why one is daily and the other twice a week, and how long to run it. This page covers the protocols that circulate, what the compound pages say about each half, and where the combination adds nothing. For a head to head on the two compounds, see BPC-157 vs TB-500. Everything here is educational background, not a treatment plan.
Why people combine BPC-157 and TB-500
BPC-157's strongest rodent data is on VEGF signaling and the FAK-paxillin pathway that moves tendon fibroblasts into a cut. TB-500 regulates actin, which governs how cells change shape and migrate, and it dampens inflammatory cytokines while recruiting progenitor cells. The theory is that one builds the supply lines and the other moves the workers. It is a reasonable theory with no combination study behind it.
BPC-157 is often injected as close to the injury as is practical, though the rodent studies show benefit with systemic dosing too. TB-500 is small and water soluble and distributes through the whole body, so the injection site does not matter. Together they cover the injury you know about and whatever else is nagging in the background.
BPC-157 clears from plasma in under 30 minutes, so it is dosed once or twice daily to keep growth factor signaling going at the injury. TB-500 is dosed twice weekly during loading because the community assumes it saturates tissue and keeps acting after it leaves the blood. That assumption has never been measured, but it is why the two schedules look so different and why a pre-mixed blend is awkward.
Neither peptide fixes a structural tear, a full rupture or a joint that needs surgery. Neither has human data for sports injury. If a tendon has not improved after 6 to 8 weeks on the pair, a third compound is not the answer; imaging and a clinician are.
Wolverine stack dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| BPC-157 | 250 to 500 mcg | once or twice daily | subcutaneous near the injury or in the abdomen, any time of day |
| TB-500 | 2 to 2.5 mg | twice weekly for 4 to 6 weeks, then 2 mg every 1 to 2 weeks | subcutaneous in the abdomen, site does not need to be near the injury |
Most reported protocols run 4 to 8 weeks for BPC-157, which lines up with the 4 to 6 week TB-500 loading phase. After that people either stop both once the injury has healed or drop TB-500 to a maintenance dose of 2 mg every one to two weeks. A break of 2 to 4 weeks for BPC-157 and 4 to 8 weeks for TB-500 is the common pattern before any repeat.
- •The TB-500 loading phase is a community convention, not a trial result. Many people skip it and dose 2 to 2.5 mg twice weekly for the whole run.
- •The dosage of each does not change because they are stacked. Acute injuries tend toward the top of the BPC-157 range, 500 mcg twice daily; chronic tendon issues usually sit at 250 to 500 mcg once daily.
- •Rotate sites. Many people give BPC-157 near the injury and TB-500 in the belly so any injection reaction is easy to trace to one compound.
- •Never inject into a tendon or joint capsule. Subcutaneous near the area is what people mean by local.
Work out syringe units for any of these in the dosage calculator.
Can you mix BPC-157 and TB-500 in one syringe?
BPC-157 and TB-500 are both reconstituted in bacteriostatic water and many people draw both into one syringe for a single injection. There is no published stability data on the mixture, but no known chemical conflict either, and no copper or pH issue of the kind that complicates GHK-Cu. Several vendors sell a pre-mixed BPC-157 and TB-500 blend in one vial, commonly 5 mg of each or 10 mg of each, and the practical problem with a blend is scheduling rather than chemistry: BPC-157 is daily and TB-500 is twice weekly, so a blend forces both on the same days at a fixed ratio. The reconstitution guide covers mixing volumes for either approach.
What to expect, week by week
- Days 1 to 7
Reduced pain and swelling at the injury is the most common early report from BPC-157. Some people feel briefly tired, flushed or lightheaded after the first TB-500 doses.
- Week 2 to 4
Better range of motion and less stiffness, which is where both compound pages put the earliest functional change. Rodent tendon studies show measurable differences within this window.
- Week 4 to 6
Load tolerance improves in tendon and muscle injuries. This is the end of the TB-500 loading phase and the point where most people judge whether the stack is working.
- Beyond week 6
Chronic injuries keep improving slowly or plateau. If nothing has changed by week 8, more of the same is unlikely to help.
Side effects and cautions
- ▲Injection site redness, mild irritation or bruising from either peptide
- ▲Fatigue, lethargy or a head rush for a few hours after larger TB-500 doses
- ▲Headache or brief dizziness after a dose
- ▲Nausea or a warm flush shortly after injection
- ▲Lightheadedness on standing, more likely if you also take blood pressure medication
- ▲Rare reports of mood changes with BPC-157
- ■Active or recent cancer. Both peptides drive blood vessel growth and cell migration, and thymosin beta-4 is expressed in many tumor types. This is the clearest reason to skip the stack.
- ■Tested athletes. Both are WADA prohibited and TB-500 is widely screened for.
- ■Anyone on anticoagulants. BPC-157 affects the nitric oxide system and vessel growth in animals, and its effect on clotting in people is unknown.
- ■A suspected rupture, fracture, or a joint that locks or gives way. That needs imaging first, not peptides.
The Wolverine stack makes sense for someone with a soft tissue injury that is not improving on rest and rehab, who understands that the evidence is rodent studies, veterinary use and anecdote, and who has already ruled out anything that needs surgery. The two peptides cover different mechanisms and different reach, so running both is defensible if the budget allows. It is not a good first move. A single tendon, a muscle strain or a gut complaint is usually a BPC-157 job on its own. Someone whose main complaint is whole body stiffness or several old injuries might start with TB-500 alone. Adding the second compound only when the first has clearly done something is how to learn which one helped. Anyone with a cancer history, on blood thinners, or subject to drug testing has good reason to leave both alone. This page is educational and not medical advice; a sports medicine clinician is the right person to rule out a tear before any of this.
Wolverine stack: frequently asked
Can you mix BPC-157 and TB-500 in the same syringe?
Yes, many people do, and vendors sell them as a blend. No stability study exists, but there is no known conflict either. The downside is scheduling: BPC-157 is daily and TB-500 is twice weekly, so mixing only works on the days both are due. Separate syringes let you follow each schedule properly.
How long should you run the Wolverine stack?
4 to 8 weeks is typical. That covers the 4 to 6 week TB-500 loading phase and the usual BPC-157 run. People with a healed injury stop there. Those still improving drop TB-500 to 2 mg every one to two weeks and keep BPC-157 going a few more weeks, then take a break. See peptide cycling for the general logic.
Do you need the TB-500 loading phase?
No. Loading at 2 to 2.5 mg twice weekly for 4 to 6 weeks is a community convention meant to saturate tissue quickly. It did not come from a human trial. Plenty of people run twice weekly for the whole cycle and never move to a maintenance dose.
Why is BPC-157 daily but TB-500 only twice a week?
BPC-157 leaves plasma in under 30 minutes, and the growth factor signaling it starts at the injury needs repeated exposure. TB-500 has a plasma half-life of about 1 to 2 hours, but the community schedule rests on the idea that it saturates tissue and keeps acting for days. That is an assumption, not a measured fact, which is worth knowing before copying it.
What is the Wolverine stack dosage?
Reported protocols use BPC-157 at 250 to 500 mcg once or twice daily and TB-500 at 2 to 2.5 mg twice weekly, the same ranges as each compound alone. The peptide dosage chart lists both, and the comparison page explains why one is in micrograms and the other in milligrams.
Does the Wolverine stack work orally?
Half of it. BPC-157 is acid stable and oral capsules are used for gut complaints, but for tendon injuries most people inject because systemic absorption from oral dosing is uncertain. TB-500 has no oral form that does anything. See oral vs injectable BPC-157.
Related reading
Skin, scar and post-procedure healing
Healing with inflammation and gut support
Gut lining repair and inflammation control
Which healing peptide should you start with, and do you need both?
Guide
Guide
Guide
Dosage
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Sources
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 2003
- Thymosin beta 4 accelerates wound healing. Journal of Investigative Dermatology, 1999
- Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature, 2004